Today in Biology — Sep 1

[THEO] Alright, Mara, let's dive into "Today in Biology." What's really shaping the landscape for scientists right now?

[DR. MARA] Theo, I'd say the biggest signal is coming from the Department of Energy, specifically around their Genesis Mission. It’s a massive push to integrate AI into scientific discovery.

[THEO] Okay, so Genesis Mission. That sounds, uh, biblical. What exactly is it? For those of us who aren't steeped in DOE initiatives, what's the big picture here?

[DR. MARA] It's essentially a national initiative to create what Darío Gil, the Under Secretary for Science, calls an "Internet of Science." Think of it as a unified platform. It's meant to connect AI models, AI agents, and scientific instruments – all working together to accelerate research.

[THEO] So, like, a grand centralized brain for all our scientific data and AI tools? Picture this: instead of a bunch of individual labs running their own simulations, you've got this enormous, interconnected system where AI can pull data from one experiment, learn from it, and then inform a totally different experiment somewhere else?

[DR. MARA] Precisely. The goal is to dramatically speed up the entire scientific pipeline, from hypothesis generation to experimental design and data analysis, particularly in areas relevant to the DOE’s mission, like materials science and environmental management. For engineering biology, this means potentially faster cycles of design-build-test-learn, especially for things like optimizing bioproduction or bioremediation.

[THEO] And we're seeing MIT researchers jumping in, UNC getting a big award for rare disease AI data... it sounds like everyone's getting on board. But what does this mean for the everyday biologist? Is it just for the big national labs, or will this trickle down to university research?

[DR. MARA] While national labs are certainly central—we're seeing sites like the Savannah River Site at the core of this AI-accelerated innovation—the intent is for this "Internet of Science" to be broadly accessible. MIT's involvement, with 15 collaborative projects, signals that university researchers are very much part of the foundational work. UNC's $35 million award to build the largest data resource for rare disease AI, supported by ARPA-H, points to the broader impact on health research, too. The vision is truly cross-institutional.

[THEO] So, the tide is definitely turning towards AI-driven, highly integrated science. But it's not all smooth sailing, right? I'm seeing some murmurs about other agencies.

[DR. MARA] Indeed. There's been considerable discussion, for instance, about the National Institutes of Health. The current Director, Jay Bhattacharya, has stated he wants to restore trust in the agency, but some current and former employees are suggesting his approach might be having the opposite effect. It's a complex situation with varied perspectives on how best to lead such a crucial organization.

[THEO] And then the NSF? I saw something about them dissolving divisions.

[DR. MARA] Yes, the National Science Foundation recently made a significant change to its biological sciences directorate. They've dissolved divisions that biologists had aimed at for decades. Now there's a "BIO Core" with a substantial budget—around $280 million supporting 250 to 300 awards—but without the specific, targeted programs that researchers were accustomed to.

[THEO] So, it's a big pot of money, but less clear exactly where to aim your grant proposal. It sounds like a shift towards broader, perhaps more interdisciplinary, proposals, but it could also introduce some uncertainty for researchers used to very specific calls. It's almost like the scientific funding landscape is becoming more fluid, less rigidly defined, but also potentially more competitive in a different way.

[DR. MARA] That's a fair assessment. It requires researchers to adapt their strategies, potentially emphasizing broader scientific impact rather than fitting into a narrow program description. It's a significant change for a field that relies heavily on consistent funding structures.

[THEO] Fascinating. So we've got this massive, ambitious AI-driven push from the DOE, a bit of political turbulence at NIH, and a structural shake-up at NSF. It really paints a picture of a field in flux, doesn't it? From the outside, it looks like a lot of big moves, a lot of repositioning.

[DR. MARA] It does. These are fundamental shifts in how science is funded, organized, and executed at a national level. For engineering biology, particularly, the Genesis Mission's emphasis on AI and data integration could be transformative, offering unprecedented tools and platforms.

[THEO] Alright, so that's the big picture. But what's got people buzzing, you know, at the water cooler, or more likely, on social platforms?

[DR. MARA] Well, there are a few interesting discussions. One that caught attention was the potential link between the shingles vaccine and a reduced risk of heart disease and heart failure, based on a study of over 70,000 people.

[THEO] Oh, that's wild. You get a vaccine for one thing, and it might have a bonus effect for another. It’s like finding out your coffee maker can also make toast.

[DR. MARA] A bit. Then there was discussion around studies suggesting that the brains of individuals with depression appear to produce fewer new neurons compared to those without the disorder. And, a more unusual one: reports of scientists extracting mitochondria from a woman's leg muscles and injecting them into her eyes to treat severe blindness.

[THEO] Wow. Mitochondria as a therapeutic? That's really pushing the boundaries of what we understand about cellular repair. It's a bold move, and I'll be curious to see where that line of research goes. Thanks, Mara, for unpacking today's biology landscape. It’s certainly a dynamic time to be in science.